ROS1 and non-small cell lung carcinoma: EML4-ALK is expressed in 3–5% of NSCLC cases [176] and crizotinib, an inhibitor of ALK, c-MET and ROS1, was granted accelerated approval by the Food and Drug Administration (FDA) in 2011 as a therapeutic drug for ALK-positive NSCLC.